Advertisement
Full length article| Volume 60, ISSUE 6, P810-816, July 01, 2022

Implications of the Quality of Life Metric in head and neck cancer

Published:December 12, 2021DOI:https://doi.org/10.1016/j.bjoms.2021.12.005
Implications of the Quality of Life Metric in head and neck cancer
Previous ArticleHow effective is a thick plate on stabilisation in 10 mm mandibular advancement?
Next ArticleFacial trauma education within two English medical schools

      Abstract

      Across England the NHS (National Health Service) has set in place a national survey that invites cancer patients to report their quality of life around 18 months after their diagnosis. The two questionnaires are the EQ-5D-5L and EORTC C30. For head and neck cancer (HNC) several factors will affect patients’ characteristics and response rates at the 18-month window. There were three aims of this study: to account for drop-out over the first 18 months, to report the characteristics of responders in comparison with the whole cohort, and to summarise the health-related quality of life (HRQoL) outcomes (EQ-5D-5L and EORTC QLQ-C30). Patients treated with curative intent who were cancer-free at 15 months were sent a postal survey 16 months after diagnosis, with a second reminder at 18 months. Of the 256 patients analysed, 187 were alive at the 15-month follow-up window, 20 of whom were living with recurrence. Survival was related to tumour stage, treatment intent, and mode of treatment. A total of 109 (67%) responded and the response rate was better from older patients. Older patients reported better HRQoL across all measures apart from EQ-5D-5L mobility and EORTC physical functioning, while patients living in more deprived neighbourhoods reported worse HRQoL across all measures apart from loss of appetite. Other than a tendency for a worse HRQoL in patients having surgery with free-flap transfer, there were no obvious consistent differences by tumour stage, site, or treatment. In conclusion, when reflecting on the findings of the National QoL Metric (QoLM) in HNC, it will be important to consider the influence of survivorship and response rates.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to British Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. Cancer quality of life survey. NHS England; 2021. Available from URL: http://www.cancerqol.england.nhs.uk (last accessed 17 February 2022).

        View in Article

      2. EQ-5D-5L: about. EuroQol Research Foundation. Available from URL: https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/ (last accessed17 February 2022).

        View in Article

      3. Quality of life of cancer patients. EORTC; 2021. Available from URL: https://qol.eortc.org/questionnaire/eortc-qlq-c30/ (last accessed 17 February 2022).

        View in Article

      4. Rogers SN, Gelcich S, Glaser A, et al; NHS England Cancer Quality of Life Working and Steering Groups. Cancer quality of life metric project – lessons learned from an implementation pilot; 2019 Available from URL: https://www.macmillan.org.uk/_images/quality-of-life_tcm9-355687.pdf (last accessed 17 February 2022).

        View in Article

      5. Personalised care and improving quality of life outcomes. NHS England; 2021. Available from URL: https://www.england.nhs.uk/cancer/living/ (last accessed 17 February 2022).

        View in Article
        • Begbie F.D.
        • Douglas C.M.
        • Finlay F.
        • et al.
        Palliative intent treatment for head and neck cancer: an analysis of practice and outcomes.
        J Laryngol Otol. 2019; 133: 313-317
        View in Article
        • Grégoire V.
        • Lefebvre J.L.
        • Licitra L.
        • et al.
        EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2010; 21: v184-v186
        View in Article

      8. Rogers SN. Search the database. HaNDLE-on-QoL; 2021. Available from URL: http://www.handle-on-qol.com/Search+the+database.aspx (last accessed17 February 2022).

        View in Article

      9. English indices of deprivation 2019: postcode lookup; 2015. Available from URL: https://imd-by-postcode.opendatacommunities.org/imd/2019 (last accessed 17 February 2022).

        View in Article

      10. NHS cancer programme: quarterly report October to December 2020. NHS. Available from URL: https://www.england.nhs.uk/wp-content/uploads/2019/12/nhs-cancer-programme-update-report-october-to-december-2020.pdf (last accessed 17 February 2022).

        View in Article
        • Elmqvist M.A.
        • Jordhøy M.S.
        • Bjordal K.
        • et al.
        Health-related quality of life during the last three months of life in patients with advanced cancer.
        Support Care Cancer. 2009; 17: 191-198
        View in Article
        • Rolstad S.
        • Adler J.
        • Rydén A.
        Response burden and questionnaire length: is shorter better?.
        A review and meta-analysis. Value Health. 2011; 14: 1101-1108
        View in Article
        • Noel C.W.
        • Keshavarzi S.
        • Forner D.
        • et al.
        Construct validity of the EuroQoL-5 Dimension and the Health Utilities Index in head and neck cancer.
        Otolaryngol Head Neck Surg. 2021; (Online ahead of print)https://doi.org/10.1177/01945998211030173
        View in Article
        • Jones D.A.
        • Mistry P.
        • Dalby M.
        • et al.
        Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
        Eur J Cancer. 2020; 124: 178-185
        View in Article
        • Mehanna H.
        • Wong W.L.
        • McConkey C.C.
        • et al.
        PET-CT surveillance versus neck dissection in advanced head and neck cancer.
        N Eng J Med. 2016; 374: 1444-1454
        View in Article
        • Pottel L.
        • Lycke M.
        • Boterberg T.
        • et al.
        G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy.
        BMC Cancer. 2015; 15: 875
        View in Article
        • Truong M.T.
        • Zhang Q.
        • Rosenthal D.I.
        • et al.
        Quality of life and performance status from a substudy conducted within a prospective phase 3 randomized trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for locally advanced head and neck carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.
        Int J Radiat Oncol Biol Phys. 2017; 97: 687-699
        View in Article

      Article Info

      Publication History

      Published online: December 12, 2021
      Accepted: December 2, 2021
      Received in revised form: November 29, 2021
      Received: October 13, 2021

      Identification

      DOI: https://doi.org/10.1016/j.bjoms.2021.12.005

      Copyright

      © 2021 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX